DK1734995T3 - Monoklonale antistoffer og hepatocyytvækstfaktor - Google Patents
Monoklonale antistoffer og hepatocyytvækstfaktorInfo
- Publication number
- DK1734995T3 DK1734995T3 DK04781281.3T DK04781281T DK1734995T3 DK 1734995 T3 DK1734995 T3 DK 1734995T3 DK 04781281 T DK04781281 T DK 04781281T DK 1734995 T3 DK1734995 T3 DK 1734995T3
- Authority
- DK
- Denmark
- Prior art keywords
- growth factor
- hepatocyte growth
- monoclonal antibodies
- pharmaceutical composition
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/825,060 US20040208876A1 (en) | 2003-04-18 | 2004-04-15 | Monoclonal antibodies to hepatocyte growth factor |
PCT/US2004/026565 WO2005107800A1 (en) | 2004-04-15 | 2004-08-13 | Monoclonal antibodies to hepatocyte growth factor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1734995T3 true DK1734995T3 (da) | 2010-10-25 |
Family
ID=35320045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04781281.3T DK1734995T3 (da) | 2004-04-15 | 2004-08-13 | Monoklonale antistoffer og hepatocyytvækstfaktor |
Country Status (26)
Country | Link |
---|---|
US (5) | US20040208876A1 (da) |
EP (2) | EP2204191A1 (da) |
JP (2) | JP4594381B2 (da) |
KR (1) | KR101072736B1 (da) |
CN (1) | CN1964738A (da) |
AT (1) | ATE473760T1 (da) |
AU (1) | AU2004319276C1 (da) |
BR (1) | BRPI0418745A (da) |
CA (1) | CA2563080C (da) |
CR (1) | CR8698A (da) |
CY (1) | CY1110783T1 (da) |
DE (1) | DE602004028168D1 (da) |
DK (1) | DK1734995T3 (da) |
ES (1) | ES2346886T3 (da) |
HK (1) | HK1094167A1 (da) |
HR (1) | HRP20100521T1 (da) |
IL (1) | IL178474A (da) |
MX (1) | MXPA06011822A (da) |
NO (1) | NO20065227L (da) |
NZ (1) | NZ550324A (da) |
PL (1) | PL1734995T3 (da) |
PT (1) | PT1734995E (da) |
RU (1) | RU2361879C2 (da) |
SI (1) | SI1734995T1 (da) |
WO (1) | WO2005107800A1 (da) |
ZA (1) | ZA200609407B (da) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
CN103880955A (zh) * | 2003-07-18 | 2014-06-25 | 安姆根有限公司 | 肝细胞生长因子的特异性结合物 |
NZ552485A (en) * | 2004-08-05 | 2009-11-27 | Genentech Inc | Humanized anti-cmet antagonists |
BRPI0611009A2 (pt) * | 2005-06-02 | 2010-08-10 | Galaxy Biotech Llc | usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização |
AU2006300234B2 (en) | 2005-10-14 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
KR101239051B1 (ko) | 2005-10-21 | 2013-03-04 | 추가이 세이야쿠 가부시키가이샤 | 심장질환 치료제 |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
TW200803894A (en) * | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
CN104189907A (zh) | 2006-01-27 | 2014-12-10 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
EP2025346B1 (en) | 2006-04-07 | 2016-08-10 | Osaka University | Muscle regeneration promoter |
BRPI0712222B1 (pt) | 2006-06-02 | 2021-10-13 | Aveo Pharmaceuticals, Inc. | Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina |
AR061170A1 (es) | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) |
MX2009007830A (es) | 2007-01-23 | 2009-10-07 | Univ Shinshu | Inhibidor de rechazo cronico. |
US7951368B2 (en) * | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
PE20091827A1 (es) * | 2008-04-11 | 2009-11-20 | Galaxy Biotech Llc | Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer |
US20110104161A1 (en) * | 2008-05-14 | 2011-05-05 | Burgess Teresa L | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
US10717781B2 (en) | 2008-06-05 | 2020-07-21 | National Cancer Center | Neuroinvasion inhibitor |
PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
WO2010119991A2 (en) | 2009-04-17 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Novel method of treating cancer |
CN101555912B (zh) * | 2009-04-29 | 2012-10-03 | 深圳市特辰科技股份有限公司 | 一种转轮式自锁安全制动装置及其工作方法 |
EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
ES2932398T3 (es) | 2010-05-28 | 2023-01-18 | Chugai Pharmaceutical Co Ltd | Potenciador de la respuesta de las células T antitumorales |
US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
US20140057908A1 (en) | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
SG194932A1 (en) | 2011-06-30 | 2013-12-30 | Genentech Inc | Anti-c-met antibody formulations |
CZ2011514A3 (cs) * | 2011-08-19 | 2013-01-23 | Invos, Spol. S R. O. | Biokontejner pro sber bioodpadu a komunálního odpadu |
CA2847245A1 (en) | 2011-09-09 | 2013-03-14 | Amgen Inc. | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients |
EP2758430A4 (en) | 2011-09-20 | 2015-06-03 | Lilly Co Eli | ANTI-C-MET ANTIBODY |
EP2873422A4 (en) | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | PHARMACEUTICAL PREPARATION FOR INJECTION |
EP2708556B1 (en) | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
US9481725B2 (en) | 2013-03-14 | 2016-11-01 | Alderbio Holdings, Llc | Antibodies to HGF and compositions containing |
KR20150140685A (ko) * | 2013-03-14 | 2015-12-16 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | Hgf에 대한 항체 및 이를 포함하는 조성물 |
WO2015031578A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Hgf assay |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
EP3698808A4 (en) | 2017-10-20 | 2021-07-14 | Hyogo College Of Medicine | MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US722041A (en) * | 1902-11-24 | 1903-03-03 | Mail Belting Company | Conveyer-belt. |
JP2564486B2 (ja) | 1986-07-14 | 1996-12-18 | 修治 橋本 | 肝細胞増殖因子 |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
GB9003621D0 (en) | 1990-02-16 | 1990-04-11 | Imp Cancer Res Tech | Protein factor |
GB9009548D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
US5646036A (en) | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CA2258153C (en) | 1996-07-03 | 2004-08-17 | Genentech, Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
AU5588099A (en) | 1998-08-28 | 2000-03-21 | Dendreon Corporation | Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody |
WO2001034650A1 (en) | 1999-11-09 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services | Hgf-sf monoclonal antibody combinations |
WO2003010282A2 (en) | 2001-07-26 | 2003-02-06 | Eli Lilly And Company | Interleukin-1 beta antibodies |
AU2002357388A1 (en) | 2001-12-27 | 2003-07-24 | The United States Of America, As Represented By The Department Of Veterans Affairs | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
AU2003270118A1 (en) | 2002-08-30 | 2004-03-19 | F. Hoffmann-La Roche Ag | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
PL1636593T3 (pl) | 2003-06-06 | 2009-08-31 | Genentech Inc | Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met. |
WO2005007193A2 (en) | 2003-07-07 | 2005-01-27 | Vande Woude, George, F. | Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
CN103880955A (zh) * | 2003-07-18 | 2014-06-25 | 安姆根有限公司 | 肝细胞生长因子的特异性结合物 |
KR100556660B1 (ko) * | 2003-11-11 | 2006-03-10 | 국립암센터 | Hgf의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
BRPI0611009A2 (pt) | 2005-06-02 | 2010-08-10 | Galaxy Biotech Llc | usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
-
2004
- 2004-04-15 US US10/825,060 patent/US20040208876A1/en not_active Abandoned
- 2004-08-13 NZ NZ550324A patent/NZ550324A/en not_active IP Right Cessation
- 2004-08-13 RU RU2006140257/13A patent/RU2361879C2/ru not_active IP Right Cessation
- 2004-08-13 MX MXPA06011822A patent/MXPA06011822A/es active IP Right Grant
- 2004-08-13 CN CNA200480042750XA patent/CN1964738A/zh active Pending
- 2004-08-13 JP JP2007508323A patent/JP4594381B2/ja not_active Expired - Fee Related
- 2004-08-13 ZA ZA200609407A patent/ZA200609407B/xx unknown
- 2004-08-13 CA CA2563080A patent/CA2563080C/en not_active Expired - Fee Related
- 2004-08-13 PL PL04781281T patent/PL1734995T3/pl unknown
- 2004-08-13 WO PCT/US2004/026565 patent/WO2005107800A1/en active Application Filing
- 2004-08-13 AT AT04781281T patent/ATE473760T1/de active
- 2004-08-13 EP EP10160203A patent/EP2204191A1/en not_active Withdrawn
- 2004-08-13 KR KR1020067023964A patent/KR101072736B1/ko not_active IP Right Cessation
- 2004-08-13 EP EP04781281A patent/EP1734995B1/en active Active
- 2004-08-13 ES ES04781281T patent/ES2346886T3/es active Active
- 2004-08-13 PT PT04781281T patent/PT1734995E/pt unknown
- 2004-08-13 SI SI200431468T patent/SI1734995T1/sl unknown
- 2004-08-13 DK DK04781281.3T patent/DK1734995T3/da active
- 2004-08-13 AU AU2004319276A patent/AU2004319276C1/en not_active Ceased
- 2004-08-13 BR BRPI0418745-8A patent/BRPI0418745A/pt not_active IP Right Cessation
- 2004-08-13 DE DE602004028168T patent/DE602004028168D1/de active Active
-
2006
- 2006-10-05 IL IL178474A patent/IL178474A/en not_active IP Right Cessation
- 2006-10-19 CR CR8698A patent/CR8698A/es unknown
- 2006-11-14 NO NO20065227A patent/NO20065227L/no not_active Application Discontinuation
-
2007
- 2007-02-05 HK HK07101333.7A patent/HK1094167A1/xx unknown
- 2007-02-23 US US11/710,009 patent/US7494650B2/en not_active Expired - Fee Related
- 2007-06-13 US US11/818,305 patent/US7687063B2/en not_active Expired - Fee Related
-
2008
- 2008-12-22 US US12/342,059 patent/US20090104192A1/en not_active Abandoned
-
2010
- 2010-08-03 JP JP2010174810A patent/JP2011012067A/ja not_active Withdrawn
- 2010-08-30 CY CY20101100789T patent/CY1110783T1/el unknown
- 2010-09-22 HR HR20100521T patent/HRP20100521T1/hr unknown
-
2011
- 2011-06-14 US US13/160,444 patent/US20120064066A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1734995T3 (da) | Monoklonale antistoffer og hepatocyytvækstfaktor | |
MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
EA201000245A1 (ru) | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf | |
EA200700202A1 (ru) | Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей | |
WO2010054265A3 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
DK1534335T3 (da) | FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf | |
ATE437186T1 (de) | Anti-epcam-immunoglobuline | |
EA200900040A1 (ru) | Молекулы антител, которые связываются с человеческим il-17 | |
MA29595B1 (fr) | Anticorps anti-cd40 humanises et procedes d'utilisation | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
DK2109623T3 (da) | Cancerbehandling med anti-IL-1-antistoffer | |
ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
CA2725873A1 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
DK1684770T3 (da) | Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft | |
DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
EE200500012A (et) | Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks | |
AR055072A1 (es) | Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical |